Day: March 15, 2023

FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (OTCPK:STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has entered into a non-binding letter of intent (the “LOI”) with Worksite Labs, Inc. (“WSL”), setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL (the “Proposed Transaction”). “We believe the proposed merger could enhance shareholder value and strengthen the company’s operating performance,” commented...

The open source projects Grafana Phlare and Pyroscope will be merged under the name Grafana Pyroscope NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) — Grafana Labs, the company behind the world’s most ubiquitous open and composable operational dashboards, today announced that it has acquired Pyroscope, the company that created the popular open source continuous profiling project of the same name. With this acquisition, Grafana Phlare, the open source continuous profiling database that Grafana Labs launched last year, and the Pyroscope project will be merged under the new name Grafana Pyroscope. Continuous profiling has been dubbed the fourth pillar of observability (after metrics, logs, and traces). It offers developers a deeper view of resource usage of their code, allowing them to understand their application performance and optimize...

STRASBOURG, France, March 15, 2023 (GLOBE NEWSWIRE) — Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio”) at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on March 28, 2023, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., New York City time, on March 14, 2023....

SINGAPORE, March 15, 2023 (GLOBE NEWSWIRE) — Novotech, the leading Asia Pacific centred biotech CRO has published a new report on the current status of clinical trials for multi-specific monoclonal antibodies (Mabs) globally including an analysis of growth hubs across Asia Pacific, Europe, and US. The new report Multi-Specific Monoclonal Antibodies – Global Clinical Trial Landscape can be downloaded here. The report found that between 2018 and 2022 there have been over 1,000 global trials related to multi-specific Mabs, with the Asia Pacific involved in about 40% of the trials, the US about 30%, and Europe about 22%. Asia Pacific has been the fastest-growing region in multi-specific Mabs trials with a 5Y CAGR of over 37% which is nearly twice and three times the growth rates of the US and Europe respectively. The majority of multi-specific...